Novo Nordisk A/S ADR sell Morgan Stanley
Start price
29.09.25
/
50%
€45.95
Target price
29.09.26
€40.10
Performance (%)
-25.09%
Price
17.04.26
€34.42
Summary
This prediction is currently active. The price of Novo Nordisk A/S ADR has decreased since the start of the prediction. Compared to the start price this results in a performance of -25.09%. This prediction currently runs until 29.09.26. The prediction end date can be changed by Morgan_Stanley at any time. Morgan_Stanley has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Novo Nordisk A/S ADR | 7.563% | 7.563% |
| iShares Core DAX® | 3.593% | 3.931% |
| iShares Nasdaq 100 | 5.810% | 5.518% |
| iShares Nikkei 225® | 4.075% | 8.460% |
| iShares S&P 500 | 4.142% | 4.039% |
Comments by Morgan_Stanley for this prediction
In the thread Novo Nordisk A/S ADR diskutieren
Novo Nordisk A/S (NYSE:NVO) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "underweight" rating. They now have a $47.00 price target on the stock, down previously from $59.00.
Ratings data for NVO provided by MarketBeat
Stopped prediction by Morgan_Stanley for Novo Nordisk A/S ADR
Novo Nordisk A/S ADR
Start price
Target price
Perf. (%)
€95.40
23.01.24
23.01.24
€110.32
23.01.25
23.01.25
-18.03%
24.01.25
24.01.25
